Legal status in the United States
Is Liraglutide legal?
Read at FDA, DEA and WADAPublished by PepVault
Liraglutide is FDA-approved (Victoza and Saxenda, first in 2010), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
Liraglutide at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Victoza, 2010) |
| Compounding | Approved drug; FDA proposes no 503B listing |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Liraglutide is FDA-approved, as Victoza in 2010 and as Saxenda in 2014; generic liraglutide injections are approved too.
Victoza (injection)
Approved for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease. NDA 022341, first approved January 25, 2010.
- Drugs@FDA: Victoza, application 022341, U.S. Food and Drug Administration. Read .
- Victoza prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
Saxenda (injection)
Approved for weight loss and keeping it off, in adults and in children 12 and older with obesity. NDA 206321, first approved December 23, 2014.
- Drugs@FDA: Saxenda, application 206321, U.S. Food and Drug Administration. Read .
- Saxenda prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Victoza, application 022341, U.S. Food and Drug Administration. Read .
- Drugs@FDA data (openFDA): applications listing “LIRAGLUTIDE” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
Liraglutide is the active ingredient of FDA-approved drugs. On April 30, 2026 FDA proposed to keep liraglutide off the 503B bulks list, the list outsourcing facilities may compound from, finding “no clinical need.” Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.
The source: “finding no clinical need for outsourcing facilities to compound these drugs from bulk substances”
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name liraglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Liraglutide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Liraglutide FDA approved?
Liraglutide is FDA-approved, as Victoza in 2010 and as Saxenda in 2014; generic liraglutide injections are approved too.
Is Liraglutide a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Liraglutide banned in sport?
The 2026 Prohibited List doesn’t name liraglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding Liraglutide?
Liraglutide is the active ingredient of FDA-approved drugs. On April 30, 2026 FDA proposed to keep liraglutide off the 503B bulks list, the list outsourcing facilities may compound from, finding “no clinical need.” Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.